title: [Prostate cancer, antiandrogen treatment and cardiovascular risk].
abstract: OBJECTIVE
  To assess if cardiovascular risk (CVR) charts are able to identify the increased risk caused by androgen deprivation therapy (ADT) in patients with prostate cancer (PCa).
  
  
  METHODS
  Retrospective cohort study.
  
  
  METHODS
  Urban and rural health centres in the province of Ourense.
  
  
  METHODS
  Patients diagnosed with PCa who had been prescribed treatment for ADT between 2007 and 2008.
  
  
  METHODS
  Age, residence (rural/urban), staging (Gleason), diagnostic procedure and, at the beginning and end of follow-up, lipid profile, blood pressure, diagnosis of diabetes mellitus, smoking, use of antihypertensive and lipid-lowering drugs, and Framingham calibrated and ATP III indexes, were determined. Cardiovascular events were recorded during the follow-up. Each patient was his own control. Increasing age was not used in the calculation of the scores at the end of the follow up period. The scores were compared using the t-test for paired samples (SPSS 15.0).
  
  
  RESULTS
  A total of 209 cases were included. The mean (SD) age was 73.8 (8.0) years, with 64.6% of urban cases. The scores at baseline and at 12 months of follow-up were: Framingham 9.0 (4.6) and 9.2 (4.8) (P=0.5), ATP III 14.2 (1.7) and 14.2 (1.7) (P=0.9).
  
  
  CONCLUSIONS
  CVR charts do not assess the increased risk associated with androgen deprivation therapy in prostate cancer.
authors.affiliation: Centro de Salud O Carballiño, SERGAS, Ourense, Spain.
authors.forename: Santiago
authors.initials: S
authors.lastname: Reinoso Hermida
authors.forename: Gabriel J
authors.initials: GJ
authors.lastname: Díaz Grávalos
authors.forename: Aida
authors.initials: A
authors.lastname: Robles Castiñeiras
authors.forename: Clara
authors.initials: C
authors.lastname: Villar Latorre
authors.forename: Ana
authors.initials: A
authors.lastname: López González
authors.forename: Antonio
authors.initials: A
authors.lastname: Ojea Calvo
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000726:Androgen Antagonists / Q000009:adverse effects*; D002318:Cardiovascular Diseases / Q000139:chemically induced* / Q000453:epidemiology*; D015331:Cohort Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D011471:Prostatic Neoplasms / Q000188:drug therapy*; D012189:Retrospective Studies; D018570:Risk Assessment; D012307:Risk Factors
chemical_list: D000726:Androgen Antagonists